- Home
- ORBS vs KLRS Comparison
ORBS vs KLRS Comparison
Compare ORBS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORBS
- KLRS
- Stock Information
- Founded
- ORBS 1966
- KLRS 2019
- Country
- ORBS United States
- KLRS United States
- Employees
- ORBS N/A
- KLRS N/A
- Industry
- ORBS
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORBS
- KLRS Health Care
- Exchange
- ORBS Nasdaq
- KLRS Nasdaq
- Market Cap
- ORBS 47.6M
- KLRS 46.0M
- IPO Year
- ORBS N/A
- KLRS N/A
- Fundamental
- Price
- ORBS $3.11
- KLRS $5.40
- Analyst Decision
- ORBS
- KLRS Strong Buy
- Analyst Count
- ORBS 0
- KLRS 3
- Target Price
- ORBS N/A
- KLRS $21.50
- AVG Volume (30 Days)
- ORBS 2.7M
- KLRS 100.6K
- Earning Date
- ORBS 11-19-2025
- KLRS 11-12-2025
- Dividend Yield
- ORBS N/A
- KLRS N/A
- EPS Growth
- ORBS N/A
- KLRS N/A
- EPS
- ORBS N/A
- KLRS N/A
- Revenue
- ORBS $41,499,747.00
- KLRS N/A
- Revenue This Year
- ORBS N/A
- KLRS N/A
- Revenue Next Year
- ORBS N/A
- KLRS N/A
- P/E Ratio
- ORBS N/A
- KLRS N/A
- Revenue Growth
- ORBS N/A
- KLRS N/A
- 52 Week Low
- ORBS $0.98
- KLRS $2.14
- 52 Week High
- ORBS $83.12
- KLRS $15.63
- Technical
- Relative Strength Index (RSI)
- ORBS N/A
- KLRS 56.31
- Support Level
- ORBS N/A
- KLRS $4.73
- Resistance Level
- ORBS N/A
- KLRS $5.68
- Average True Range (ATR)
- ORBS 0.00
- KLRS 0.42
- MACD
- ORBS 0.00
- KLRS 0.07
- Stochastic Oscillator
- ORBS 0.00
- KLRS 77.41
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.